Cardiff Oncology, Inc., a clinical-stage biotechnology company leveraging PLK1 inhibition to develop novel therapies across a range of cancers, announced recent company highlights and financial results for the first quarter ended March 31, 2022.
May 5, 2022
· 13 min read